When people around the
world are questioning whether pharmaceutical companies are dead serious in producing a vaccine that could cure humankind of Covid-19, or whether their moneymaking agenda is to ensure that people
move from a pandemic to an endemic situation, whereby they would need to be jabbed more expensively every year to protect themselves against allegedly deadlier variants of the
virus.
If
vaccine manufacturers’ motives were to enrich themselves and their shareholders, inquiring about the shelf
life of a corona vaccine would be
like asking them an uncomfortable or taboo question, which is likely to yield a vague or unhelpful answer.